FDA, HHS and USDA Serve Up Ultra-Processed Food RFI

July 25, 2025

Reading Time : 1 min

On July 25, the U.S. Food and Drug Administration (FDA), in collaboration with the U.S. Department of Health and Human Services (HHS) and U.S. Department of Agriculture (USDA), unveiled the highly anticipated joint request for information on ultra-processed foods (UPFs). Specifically, the administration is seeking information and data to help develop a uniform definition for UPFs in the U.S. food supply.

This information request is part of the broader Make America Healthy Again (MAHA) initiative and focuses on concerns about health impacts of UPFs including links to chronic diseases such as cardiovascular disease, obesity and type 2 diabetes. The request for information (RFI) comes as several states move to advance regulations targeting food additives and UPFs.

Currently, there is no universally accepted definition of UPFs. A uniform definition is likely to serve as the foundation for future regulatory actions, including potential changes to product labeling and marketing standards.

The RFI solicits input on a range of topics, including:

  • Existing Classification Systems: What existing classifications systems or policies should be considered, and what are their strengths and limitations?
  • Ingredient-Based Criteria: How should the presence, type and proportion of ingredients influence classification?
  • Processing Methods: What physical, biological, chemical or other processes should be considered indicative of ultra-processing?
  • Terminology: Is “ultra-processed” the most appropriate term, or should alternative terminology be considered?
  • Nutritional and Other Attributes: Should factors like nutritional composition, energy density or palpability be incorporated into the definition?
  • Policy Implications: How might a standardized definition be integrated into food and nutrition policies and programs?

In addition to developing a uniform definition, FDA and the National Institutes of Health (NIH) are advancing research to investigate the health impacts of UPFs through a recently announced Nutrition Regulatory Science Program.

The RFI presents an opportunity for stakeholders to submit feedback as the administration considers policies related to UPFs. A 60-day comment period is provided, and with publication on July 25, 2025, comments are due by September 23, 2025.

Share This Insight

Previous Entries

Eye on FDA

February 17, 2026

On February 3, 2026, the Consolidated Appropriations Act, 2026 (P.L. 119-75) became law and marked an important milestone in the bipartisan congressional effort to reauthorize the rare pediatric disease priority review voucher program. Section 6604 of this law extends the Food and Drug Administration’s (FDA) authority to issue priority review vouchers to encourage treatments for rare pediatric diseases through September 30, 2029.

...

Read More

Eye on FDA

February 17, 2026

In case you missed it, Department of Health and Human Services Secretary Robert F. Kennedy Jr. and former Food and Drug Administration (FDA) Commissioner David Kessler appeared on 60 Minutes this past Saturday, February 15, in a segment titled “Generally Recognized as Safe.” As the title suggests, the conversation centered on FDA’s Generally Recognized as Safe (GRAS) regulatory pathway (for background, see our prior post discussing in more detail the GRAS process), as well as Commissioner Kessler’s August 2025 citizen petition urging FDA to revoke the GRAS status of refined carbohydrates used in industrial food processing (discussed in more detail in our earlier coverage of the petition).

...

Read More

Eye on FDA

February 3, 2026

On February 1, 2026, the Food and Drug Administration (FDA) officially started accepting requests to participate in the FDA PreCheck pilot program. The goal of the program is to strengthen the domestic pharmaceutical supply chain by making the review and inspection process more predictable for U.S.-based drug manufacturing facilities.

...

Read More

Eye on FDA

January 28, 2026

The Food and Drug Administration (FDA) has begun 2026 with a clear signal to the direct‑to‑consumer testing industry: self‑collection devices remain firmly within the agency’s regulatory reach, notwithstanding the 2025 court ruling on laboratory developed tests (LDTs). Last week, the agency published warning letters previously issued to four companies—Genetrace, Genovate, Germaphobix and ProDx Health—selling human immunodeficiency virus (HIV) tests that rely on unauthorized self‑collection kits.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.